MedTrace Logo

A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE

NCT00933556 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2015-10-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the feasibility, safety and efficacy of oral probiotic, VSL#3 versus oral placebo for reducing colonization by VRE.

Conditions

  • Anti-biotic Resistance

Interventions

DIETARY_SUPPLEMENT

VSL#3

6 gms of powder formulation to be given once a day for 4 weeks

DIETARY_SUPPLEMENT

sugar pill (placebo)

placebo identical to the active product will be given

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Nasia Safdar, MD, MS · University of Wisconsin Department of Medicine (Infectious Disease)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-10-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00933556 on ClinicalTrials.gov